Article Text

other Versions

PDF
Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery
  1. Christine A Kiire1,
  2. Rajarshi Mukherjee1,
  3. Neil Ruparelia2,
  4. David Keeling3,
  5. Bernard Prendergast2,
  6. Jonathan H Norris1
  1. 1Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK
  2. 2Department of Cardiology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK
  3. 3Department of Haematology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK
  1. Correspondence to Jonathan H Norris, Consultant Ophthalmic Surgeon, Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford OX3 9DU, UK; jonathan.norris{at}ouh.nhs.uk

Abstract

The management of antiplatelet and anticoagulant treatment can be challenging for the ophthalmic surgeon with the risk of impaired surgical view or potentially sight-threatening haemorrhage. With the advent of newer medications and the expanding usage of these drugs, there is a need for up-to-date guidance on the subject. This paper describes the current use of modern antiplatelet and anticoagulant drugs in the UK, and reviews the evidence of such treatments in the context of ophthalmic surgery. A multidisciplinary approach has been used to develop a guideline for the management of antiplatelet and anticoagulation treatment in elective ophthalmic surgery. Specifically, guidance is provided on when and how to stop antiplatelet and anticoagulant treatment and, importantly, when to seek specialist medical advice.

  • Treatment Surgery
  • Diagnostic tests/Investigation
  • Biochemistry

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.